Cetuximab does not enhance the activity of the standard of care for advanced biliary-tract cancer (gemcitabine plus a platinum-based agent), according to the results of a phase II trial published in The Lancet Oncology. In the chemotherapy plus cetuximab group, median progression-free survival was 6.1 months and median overall survival was 11.0 months; in the chemotherapy alone group they were 5.5 months and 12.4 months, respectively.
References
Malka, D et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 10.1016/S1470-2045(14)70212-8
Rights and permissions
About this article
Cite this article
Standard of care for advanced biliary cancer should stay as gemcitabine plus a platinum-based agent. Nat Rev Gastroenterol Hepatol 11, 395 (2014). https://doi.org/10.1038/nrgastro.2014.104
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.104
